{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:37:47Z","timestamp":1782207467077,"version":"3.54.5"},"reference-count":84,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Chronic hepatitis C virus infection is an important cause of liver cirrhosis, hepatocellular carcinoma and death. Furthermore, it is estimated that about 40\u201370% of patients develop non-hepatic alterations in the course of chronic infection. Such manifestations can be immune-related conditions, lymphoproliferative disorders and metabolic alterations with serious adverse events in the short and long term. The introduction of new Direct-Acting Antivirals has shown promising results, with current evidence indicating an improvement and remission of these conditions after a sustained virological response.<\/jats:p>","DOI":"10.3390\/pathogens13040339","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T06:28:09Z","timestamp":1713508089000},"page":"339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Chronic Hepatitis C Virus Infection, Extrahepatic Disease and the Impact of New Direct-Acting Antivirals"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-8048","authenticated-orcid":false,"given":"Nahum","family":"M\u00e9ndez-S\u00e1nchez","sequence":"first","affiliation":[{"name":"Unit Liver Research, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"},{"name":"Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0848-2000","authenticated-orcid":false,"given":"Carlos E.","family":"Coronel-Castillo","sequence":"additional","affiliation":[{"name":"Internal Medicine Section, Central Military Hospital, Mexico City 11649, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Michelle","family":"Ram\u00edrez-Mej\u00eda","sequence":"additional","affiliation":[{"name":"Unit Liver Research, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico"},{"name":"Plan of Combined Studies in Medicine (PECEM MD\/PhD), Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"ref_1","unstructured":"WHO (2024, February 06). Global Health Estimates: Leading Causes of Death. Available online: https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates\/ghe-leading-causes-of-death."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","article-title":"Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: A systematic review","volume":"7","author":"Alberts","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis\u2014Aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.3748\/wjg.v28.i41.5910","article-title":"Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions","volume":"28","author":"Liu","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_5","first-page":"100151","article-title":"Cirrhosis etiology trends in developing countries: Transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico","volume":"7","year":"2022","journal-title":"Lancet Reg. Health Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: From discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-pharmtox-011112-140254","article-title":"Direct-acting antiviral agents for hepatitis C virus infection","volume":"53","author":"Kiser","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(18)32326-2","article-title":"Direct-acting antiviral treatment for hepatitis C","volume":"393","author":"Holmes","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4254\/wjh.v10.i2.186","article-title":"Hepatitis C virus: Morphogenesis, infection and therapy","volume":"10","author":"Morozov","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jhep.2014.06.031","article-title":"Virology and cell biology of the hepatitis C virus life cycle: An update","volume":"61","author":"Dubuisson","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Alazard-Dany, N., Denolly, S., Boson, B., and Cosset, F.L. (2019). Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. Viruses, 11.","DOI":"10.3390\/v11010030"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.cmi.2016.08.025","article-title":"Hepatitis C virus: Life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy","volume":"22","author":"Dustin","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jceh.2018.07.004","article-title":"New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials","volume":"9","author":"Pecoraro","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_15","first-page":"3","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"3","author":"Cacoub","year":"2016","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMra2033539","article-title":"Extrahepatic Manifestations of Chronic HCV Infection","volume":"384","author":"Cacoub","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.cmi.2019.06.018","article-title":"Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: An 8-year prospective study","volume":"26","author":"Cheng","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"502156","DOI":"10.1155\/2012\/502156","article-title":"Hepatitis C virus infection and mixed cryoglobulinemia","volume":"2012","author":"Lauletta","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/rheumatology\/kem132","article-title":"Hepatitis C-associated mixed cryoglobulinaemia: A crossroad between autoimmunity and lymphoproliferation","volume":"46","author":"Saadoun","year":"2007","journal-title":"Rheumatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"439018","DOI":"10.1155\/2012\/439018","article-title":"Rheumatoid factor, complement, and mixed cryoglobulinemia","volume":"2012","author":"Gorevic","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3389\/fimmu.2018.01001","article-title":"The Complement System and C1q in Chronic Hepatitis C Virus Infection and Mixed Cryoglobulinemia","volume":"9","author":"Branch","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_23","first-page":"134","article-title":"Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy","volume":"3","author":"Tasleem","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41375-023-01868-2","article-title":"Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencing","volume":"37","author":"Armand","year":"2023","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/annonc\/mdx635","article-title":"From hepatitis C virus infection to B-cell lymphoma","volume":"29","author":"Bachy","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/path.1754","article-title":"Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin\u2019s lymphomas of patients with chronic HCV infection","volume":"206","author":"Libra","year":"2005","journal-title":"J. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13075-015-0766-3","article-title":"How hepatitis C virus modifies the immunological profile of Sj\u00f6gren syndrome: Analysis of 783 patients","volume":"17","author":"Gheitasi","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/1348-0421.12202","article-title":"Hepatitis C virus infection and the risk of Sj\u00f6gren or sicca syndrome: A meta-analysis","volume":"58","author":"Wang","year":"2014","journal-title":"Microbiol. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12985-023-02124-w","article-title":"Prevalence of hepatitis C virus among patients with arthralgia: Is it logic for screening?","volume":"20","author":"Othman","year":"2023","journal-title":"Virol. J."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Elgretli, W., Chen, T., Kronfli, N., and Sebastiani, G. (2023). Hepatitis C Virus-Lipid Interplay: Pathogenesis and Clinical Impact. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020271"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3748\/wjg.v27.i13.1267","article-title":"Metabolic complications of hepatitis C virus infection","volume":"27","author":"Chaudhari","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1073\/pnas.0700760104","article-title":"Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins","volume":"104","author":"Huang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/jhep.2003.50291","article-title":"Hepatitis C virus infection and incident type 2 diabetes","volume":"38","author":"Mehta","year":"2003","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3748\/wjg.v23.i9.1697","article-title":"Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review","volume":"23","author":"Desbois","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e220155","DOI":"10.1530\/JOE-22-0155","article-title":"Role of hepatic peroxisome proliferator-activated receptor \u03b3 in non-alcoholic fatty liver disease","volume":"257","author":"Lee","year":"2023","journal-title":"J. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E94","DOI":"10.2527\/jas.2007-0462","article-title":"Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes","volume":"86","author":"Lorenzo","year":"2008","journal-title":"J. Anim. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/1348-0421.13023","article-title":"Hepatitis C virus, insulin resistance, and diabetes: A review","volume":"66","author":"Alzahrani","year":"2022","journal-title":"Microbiol. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1128\/JVI.00050-12","article-title":"Hepatitis C virus activates the mTOR\/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance","volume":"86","author":"Bose","year":"2012","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(02)07339-7","article-title":"Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening","volume":"359","author":"Ishizaka","year":"2002","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/1744666X.2018.1538790","article-title":"Uncommon immune-mediated extrahepatic manifestations of HCV infection","volume":"14","author":"Romano","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.17219\/acem\/37787","article-title":"The neuropsychiatric aspect of the HCV infection","volume":"26","author":"Marcinowicz","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/B:MEBR.0000043981.89134.39","article-title":"Hepatitis C virus infection and the brain","volume":"19","author":"Tillmann","year":"2004","journal-title":"Metab. Brain. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4254\/wjh.v8.i12.545","article-title":"Hepatitis C virus and neurological damage","volume":"8","author":"Mathew","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_45","first-page":"27154","article-title":"Psychiatric care of the patient with hepatitis C: A review of the literature","volume":"12","author":"Rifai","year":"2010","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/526519","article-title":"Molecular and bioinformatic evidence of hepatitis C virus evolution in brain","volume":"197","author":"Fishman","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.3748\/wjg.v21.i8.2269","article-title":"Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview","volume":"21","author":"Adinolfi","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4254\/wjh.v5.i10.528","article-title":"Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations","volume":"5","author":"Zampino","year":"2013","journal-title":"World J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ndt\/11.supp4.22","article-title":"Type I membranoproliferative glomerulonephritis and HCV infection","volume":"11","author":"Rostoker","year":"1996","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"128382","DOI":"10.6064\/2012\/128382","article-title":"Hepatitis C virus, cryoglobulinemia, and kidney: Novel evidence","volume":"2012","author":"Fabrizi","year":"2012","journal-title":"Scientifica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jare.2016.07.004","article-title":"Hepatitis C and kidney disease: A narrative review","volume":"8","author":"Barsoum","year":"2017","journal-title":"J. Adv. Res."},{"key":"ref_52","first-page":"e27322","article-title":"Hepatitis Virus C-associated Nephropathy: A Review and Update","volume":"14","author":"Habas","year":"2022","journal-title":"Cureus"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12072-018-9915-5","article-title":"APASL clinical practice recommendation: How to treat HCV-infected patients with renal impairment?","volume":"13","author":"Kanda","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"983238","DOI":"10.3389\/fonc.2022.983238","article-title":"Chronic hepatitis C infection is associated with higher incidence of extrahepatic cancers in a Canadian population based cohort","volume":"12","author":"Darvishian","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrgastro.2017.172","article-title":"Extrahepatic cancers and chronic HCV infection","volume":"15","author":"Pol","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/jvh.13304","article-title":"Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study","volume":"27","author":"Hong","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/pds.5576","article-title":"Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers","volume":"32","author":"Lam","year":"2023","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/rheumatology\/kes209","article-title":"Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection","volume":"51","author":"Terrier","year":"2012","journal-title":"Rheumatolgy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/bs.vh.2021.06.006","article-title":"Inhibition of hepatitis C virus by vitamin D","volume":"117","author":"Murayama","year":"2021","journal-title":"Vitam. Horm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/hepr.12784","article-title":"Association between vitamin D deficiency and pre-existing resistance-associated hepatitis C virus NS5A variants","volume":"47","author":"Okubo","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Hashimoto, S., Yatsuhashi, H., Abiru, S., Yamasaki, K., Komori, A., Nagaoka, S., Saeki, A., Uchida, S., Bekki, S., and Kugiyama, Y. (2016). Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163644"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/00365521.2018.1473486","article-title":"Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication\u2014Comparison of the new direct-acting antiviral agents with the old regimens","volume":"53","author":"Carvalho","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5152\/tjg.2020.19273","article-title":"The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: Temporary? permanent?","volume":"31","author":"Sezgin","year":"2020","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11739-019-02163-8","article-title":"Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: A prospective cohort study","volume":"15","author":"Ambrosino","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","article-title":"Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis","volume":"69","author":"Petta","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/dom.14168","article-title":"Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study","volume":"22","author":"Adinolfi","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/jvh.13215","article-title":"Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance","volume":"27","author":"Russo","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11739-020-02628-1","article-title":"Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease","volume":"16","author":"Villani","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.nefro.2019.07.007","article-title":"The impact of antiviral therapy for HCV on kidney disease: A systematic review and meta-analysis","volume":"40","author":"Fabrizi","year":"2020","journal-title":"Nefrolog\u00eda"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","article-title":"Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study","volume":"61","author":"Gragnani","year":"2015","journal-title":"Hepatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.23305","article-title":"Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response","volume":"58","author":"Landau","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cgh.2018.05.021","article-title":"Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis","volume":"17","author":"Cacoub","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/apt.14845","article-title":"Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: A prospective, controlled, clinical and quality of life analysis","volume":"48","author":"Gragnani","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2016.09.158","article-title":"Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals","volume":"15","author":"Bonacci","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/hep.32281","article-title":"A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort","volume":"76","author":"Kondili","year":"2022","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Danishwar, M., Jamil, Z., Khan, S., Nakhla, M., Ahmad, I., Ali, M.A., and Lau, D.T.Y. (2022). Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure. J. Clin. Med., 11.","DOI":"10.3390\/jcm11040984"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1191843","DOI":"10.3389\/fphar.2023.1191843","article-title":"Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: A nationwide cohort study","volume":"14","author":"Fang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jvh.12518","article-title":"The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: A meta-analysis","volume":"23","author":"Arcaini","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/liv.12897","article-title":"HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents","volume":"35","author":"Carrier","year":"2015","journal-title":"Liver Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/s41375-019-0687-2","article-title":"Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"34","author":"Frigeni","year":"2020","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1634\/theoncologist.2018-0331","article-title":"Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas","volume":"24","author":"Merli","year":"2019","journal-title":"Oncologist"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29364","article-title":"Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma","volume":"67","author":"Persico","year":"2018","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/JCO.22.00668","article-title":"Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi","volume":"40","author":"Merli","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/4\/339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:30:40Z","timestamp":1760106640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/4\/339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":84,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["pathogens13040339"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13040339","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]}}}